WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018054782) COMBINATION OF PI3K-INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/054782    International Application No.:    PCT/EP2017/073308
Publication Date: 29.03.2018 International Filing Date: 15.09.2017
IPC:
C07D 471/04 (2006.01), A61K 31/437 (2006.01), A61K 31/4375 (2006.01), A61P 35/00 (2006.01)
Applicants: BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178 13353 Berlin (DE)
Inventors: LANGE, Martin; (DE)
Agent: BIP PATENTS; Alfred-Nobel-Str. 10 40789 Monheim am Rhein NRW (DE)
Priority Data:
16190377.8 23.09.2016 EP
Title (EN) COMBINATION OF PI3K-INHIBITORS
(FR) COMBINAISON D'INHIBITEURS DE LA PI3K
Abstract: front page image
(EN)The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment or prophylaxis of non-Hodgkin's lymphoma (hereinafter abbreviated to "NHL"), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (hereinafter abbreviated to "FL"), chronic lymphocytic leukaemia (hereinafter abbreviated to "CLL"), marginal zone lymphoma (hereinafter abbreviated to "MZL"), splenic marginal zone lymphoma (hereinafter abbreviated to "SMZL"), diffuse large B-cell lymphoma (hereinafter abbreviated to "DLBCL"), mantle cell lymphoma (MCL), transformed lymphoma (hereinafter abbreviated to "TL"), or peripheral T-cell lymphoma (hereinafter abbreviated to "PTCL").
(FR)La présente invention concerne des combinaisons d’au moins deux composants, le composant A et le composant B, le composant A étant un inhibiteur de la kinase PI3K, et le composant B étant le vénétoclax ou le palbociclib. Un autre aspect de la présente invention concerne l'utilisation de telles combinaisons comme décrit ici pour la préparation d'un médicament pour le traitement ou la prophylaxie d'une maladie, en particulier pour le traitement ou la prophylaxie du lymphome non hodgkinien (ci-après abrégé en " NHL "), en particulier 1ère ligne, 2ème ligne, rechute, réfractaire, indolent ou agressif non hodgkinien (NHL), en particulier le lymphome folliculaire (ci-après abrégé en " FL "), la leucémie lymphoïde chronique (ci-après abrégé en " CLL "), le lymphome de zone marginale (ci-après abrégé en " MZL "), le lymphome splénique de zone marginale (ci-après abrégé en " SMZL "), le lymphome diffus à grandes cellules B (ci-après abrégé en " DLBCL "), le lymphome à cellules du manteau (MCL), le lymphome transformé (ci-après abrégé en " TL "), ou le lymphome périphérique à lymphocytes T (ci-après abrégé en " PTCL ").
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)